Skip to the main content.
Facebook Linkedin X

Press | ​Accelerating Timelines Vital to Securing Slice of Biosimilars Market, KBI

Picture of Admin Admin Sep 3, 2017 5:10:00 AM

News

Accelerating timelines vital to securing slice of biosimilars market, KBI

By Dan Stanton+, 24-Aug-2016

Accelerated development gives biosimilars an upper hand in gaining market share, CMO KBI Biopharma told delegates in Korea yesterday.

http://www.biopharma-reporter.com/Upstream-Processing/Expediting-timelines-key-to-securing-slice-of-biosimilars-market-KBI
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate

KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate

KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology Durham,...

Read More
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization...

Read More
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Durham, North Carolina (April 1, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing...

Read More